NTI logo

Neurotech International Limited Stock Price

ASX:NTI Community·AU$18.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

NTI Share Price Performance

AU$0
-0.03 (-100.00%)
AU$0
-0.03 (-100.00%)
Price AU$0

NTI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards

Neurotech International Limited Key Details

AU$7.1m

Revenue

-AU$1.5m

Cost of Revenue

AU$8.5m

Gross Profit

AU$12.4m

Other Expenses

-AU$3.9m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.003
120.85%
-54.45%
0%
View Full Analysis

About NTI

Founded
2016
Employees
n/a
CEO
Anthony Filippis
WebsiteView website
neurotechinternational.com

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.

Recent NTI News & Updates

Recent updates

No updates